10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2021 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 18, 2022) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Net Sales | $ 43,075 | 34,608 | 31,904 |
| Cost of products sold, excluding amortization of intangible assets | 18,537 | 15,003 | 13,231 |
| Amortization of intangible assets | 2,047 | 2,132 | 1,936 |
| Research and development | 2,742 | 2,420 | 2,440 |
| Selling, general and administrative | 11,324 | 9,696 | 9,765 |
| Total Operating Cost and Expenses | 34,650 | 29,251 | 27,372 |
| Operating Earnings | 8,425 | 5,357 | 4,532 |
| Interest expense | 533 | 546 | 670 |
| Interest income | (43) | (46) | (94) |
| Net foreign exchange (gain) loss | 1 | (8) | 7 |
| Debt extinguishment costs | 63 | ||
| Other (income) expense, net | (277) | (103) | (191) |
| Earnings from Continuing Operations Before Taxes | 8,211 | 4,968 | 4,077 |
| Taxes on Earnings from Continuing Operations | 1,140 | 497 | 390 |
| Earnings from Continuing Operations | 7,071 | 4,471 | 3,687 |
| Net Earnings from Discontinued Operations, net of taxes | 24 | ||
| Net Earnings | 7,071 | 4,495 | 3,687 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations | 3.97 | 2.51 | 2.07 |
| Discontinued Operations | 0.01 | ||
| Net Earnings | 3.97 | 2.52 | 2.07 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations | 3.94 | 2.49 | 2.06 |
| Discontinued Operations | 0.01 | ||
| Net Earnings | 3.94 | 2.50 | 2.06 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share | 1,775 | 1,773 | 1,768 |
| Dilutive Common Stock Options | 14 | 13 | 13 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,789 | 1,786 | 1,781 |
| Outstanding Common Stock Options Having No Dilutive Effect | 9 | 61 | |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2021 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 18, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Net Earnings | $ 7,071 | 4,495 | 3,687 |
| Foreign currency translation gain (loss) adjustments | (980) | 65 | (12) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $340 in 2021, $(79) in 2020 and $(238) in 2019 | 1,201 | (331) | (814) |
| Net gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $63 in 2021, $(87) in 2020 and $(17) in 2019 | 351 | (215) | (53) |
| Other Comprehensive Income (Loss) | 572 | (481) | (879) |
| Comprehensive Income | 7,643 | 4,014 | 2,808 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | (5,839) | (4,859) | (4,924) |
| Net actuarial (losses) and prior service (cost) and credits | (2,670) | (3,871) | (3,540) |
| Cumulative gains (losses) on derivative instruments designated as cash flow hedges | 135 | (216) | (1) |
| Accumulated other comprehensive income (loss) | (8,374) | (8,946) | (8,465) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2021 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 18, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 7,071 | 4,495 | 3,687 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 1,491 | 1,195 | 1,078 |
| Amortization of intangible assets | 2,047 | 2,132 | 1,936 |
| Share-based compensation | 640 | 546 | 519 |
| Investing and financing losses, net | 55 | 425 | 184 |
| Loss on extinguishment of debt | 63 | ||
| Trade receivables | (383) | (924) | (275) |
| Inventories | (456) | (493) | (593) |
| Prepaid expenses and other assets | (312) | (627) | (138) |
| Trade accounts payable and other liabilities | 1,288 | 1,766 | 220 |
| Income taxes | (908) | (614) | (545) |
| Net Cash From Operating Activities | 10,533 | 7,901 | 6,136 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,885) | (2,177) | (1,638) |
| Acquisitions of businesses and technologies, net of cash acquired | (187) | (42) | (170) |
| Proceeds from business dispositions | 134 | 58 | 48 |
| Purchases of investment securities | (173) | (83) | (103) |
| Proceeds from sales of investment securities | 77 | 10 | 21 |
| Other | 26 | 19 | 27 |
| Net Cash From (Used in) Investing Activities | (2,008) | (2,215) | (1,815) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | (204) | 2 | |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 4 | 1,281 | 1,842 |
| Repayments of long-term debt and debt with maturities over 3 months | (48) | (1,333) | (3,441) |
| Purchases of common shares | (2,299) | (403) | (718) |
| Proceeds from stock options exercised | 255 | 245 | 298 |
| Dividends paid | (3,202) | (2,560) | (2,270) |
| Other | (11) | ||
| Net Cash From (Used in) Financing Activities | (5,494) | (2,779) | (4,289) |
| Effect of exchange rate changes on cash and cash equivalents | (70) | 71 | (16) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 2,961 | 2,978 | 16 |
| Cash and Cash Equivalents, Beginning of Year | 6,838 | 3,860 | |
| Cash and Cash Equivalents, End of Year | 9,799 | 6,838 | 3,860 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,941 | 970 | 930 |
| Interest paid | 544 | 549 | 677 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2021 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2021 10-K (Filed: Feb 18, 2022) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2021 | Dec 31, 2020 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 9,799 | 6,838 |
| Investments, primarily bank time deposits and U.S. treasury bills | 450 | 310 |
| Trade receivables, less allowances of - 2021: $519; 2020: $460 | 6,487 | 6,414 |
| Inventories: | ||
| Finished products | 3,081 | 3,030 |
| Work in process | 694 | 712 |
| Materials | 1,382 | 1,270 |
| Total inventories | 5,157 | 5,012 |
| Other prepaid expenses and receivables | 2,346 | 1,867 |
| Total current assets | 24,239 | 20,441 |
| Investments | 816 | 821 |
| Property and equipment, at cost: | ||
| Land | 525 | 538 |
| Buildings | 4,007 | 4,014 |
| Equipment | 13,528 | 12,884 |
| Construction in progress | 1,304 | 1,357 |
| Property and equipment, at cost | 19,364 | 18,793 |
| Less: accumulated depreciation and amortization | 10,405 | 9,764 |
| Net property and equipment | 8,959 | 9,029 |
| Intangible assets, net of amortization | 12,739 | 14,784 |
| Goodwill | 23,231 | 23,744 |
| Deferred income taxes and other assets | 5,212 | 3,729 |
| Total Assets | 75,196 | 72,548 |
| Liabilities and Shareholders' Investment | ||
| Current liabilities: | ||
| Short-term borrowings | 0 | 213 |
| Trade accounts payable | 4,408 | 3,946 |
| Salaries, wages and commissions | 1,625 | 1,416 |
| Other accrued liabilities | 5,181 | 5,165 |
| Dividends payable | 831 | 798 |
| Income taxes payable | 306 | 362 |
| Current portion of long-term debt | 754 | 7 |
| Total current liabilities | 13,105 | 11,907 |
| Long-term debt | 17,296 | 18,527 |
| Post-employment obligations and other long-term liabilities | 8,771 | 9,111 |
| Commitments and contingencies | ||
| Shareholders' investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2021: 1,985,273,421; 2020: 1,981,156,896 | 24,470 | 24,145 |
| Common shares held in treasury, at cost - Shares: 2021: 221,191,228; 2020: 209,926,622 | (11,822) | (10,042) |
| Earnings employed in the business | 31,528 | 27,627 |
| Accumulated other comprehensive income (loss) | (8,374) | (8,946) |
| Total Abbott Shareholders' Investment | 35,802 | 32,784 |
| Noncontrolling interests in subsidiaries | 222 | 219 |
| Total Shareholders' Investment | 36,024 | 33,003 |
| Total Liabilities and Shareholders' Investment | 75,196 | 72,548 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |